

Docket No.: 05432/100M810-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Garrick Paul Smith et al.

Application No.: 10/551,737

Confirmation no.: 4333

Filed: September 29, 2005

Art Unit: Not Yet Assigned

For: AROMATIC OXYPHENYL AND
AROMATIC SULFANYLPHENYL
DERIVATIVES

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant submits herewith a copy of each cited foreign patent document and non-patent literature document in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Also submitted herewith is an International Search Report dated August 5, 2004 that was issued during the international stage of the present application for PCT/DK2004/000290.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

No fee is believed due with this Information Disclosure Statement. However, if a fee is determined to be due, the Commissioner is authorized to charge any deficiency of up to \$300.00 to Deposit Account No. 04-0100.

Dated: June 5, 2006

Respectfully submitted,

By 

Mitchell Bernstein, Ph.D.

Registration No.: 46,550

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/551,737
				Filing Date	September 29, 2005
				First Named Inventor	Garrick Paul Smith
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	05432/100M810-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	EP-1284257-A2	02-19-2003	Pfizer Products		
	BB	WO-97/20553-A1	06-12-1997	Javitt		
	BC	WO-97/45115-A1	12-04-1997	Trophix Pharmaceuticals		
	BD	WO-02/00602-A	01-03-2002	Pfizer Products		
	BE	WO-03/000646-A1	01-03-2003	Pfizer Products		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	BARTL et al., "2-chloro-7-fluoro- and 2-chloro-3,7-difluoro-11-[4-(4-fluoroalkyl)piperazino]-10,11-dihydrodibenzo-[b,f]thiepins and related compounds; long acting tranquilizers," Collection Czechoslovak Chem. Commun. 1981, 46, 141.	
	CB	FIESER et al., "Synthesis of 6-methylaceanthrene," J. Am. Chem. Soc. 1952, 74, 536.	
	CC	GILMAN et al., "The yields of some organomagnesium and organolithium compounds," Recl. Trav. Chim. Pays-Bas 1935, 584.	
	CD	HARDER et al., "The molecular structure of 1-lithio-2-methoxybenzene in the solid state and in solution," J. Organomet. Chem. 1989, 364, 1-16.	
	CE	HERESCO-LEVY et al., "Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder," The International Journal of Neuropsychopharmacology 2002, 5:301-307.	
	CF	IWAO, "Directed lithiation of chlorobenzenes. Regioselectivity and application to a short synthesis of benzocyclobutenes," J. Org. Chem. 1990, 55, 3622-3627.	
	CG	JAVITT et al., "Amelioration of negative symptoms in schizophrenia by glycine," Am. J. Psychiatry 1994, 151, 1234-1236.	
	CH	LEIDERMAN et al., "Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial," Biol. Psychiatry 1996, 39, 213-215.	
	CI	MITSUBU, "The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products," Synthesis 1981, 1.	
	CJ	RISON et al., "Long-term potentiation and N-methyl-D-aspartate receptors: foundations of memory and neurologic disease?" Neurosci. Biobehav. Rev. 1995, 19, 533-552.	
	CK	SAMOSHIN et al., "Novel reaction: brominative aromatization of 2-alkyl(aryl)thio cyclohexanones," Tet. Lett. 1994, 35, 7413-7414.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/551,737	
			Filing Date	September 29, 2005	
			First Named Inventor	Garrick Paul Smith	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	05432/100M810-US1

CL	SCHOPFER, "A general palladium-catalysed synthesis of aromatic and heteroaromatic thioethers," Tetrahedron 2001, 57, 3069-3073.	
CM	STILLE et al., "Palladium-catalysed coupling of aryl halides with (trimethylstannyl)diphenylphosphine and (trimethylsilyl)diphenylphosphine," J. Org. Chem. 1987, 52, 748-753.	
CN	TRUONG et al., "Glycine involvement in DDT-induced myoclonus," Movement Disorders 1988, 3, 77-87.	
CO	YAKSH, "Behavioral and autonomic correlates of the tactile evoked allodynia produced by spinal glycine inhibition: effects of modulatory receptor systems and excitatory amino acid antagonists," Pain 1989, 37, 111-123.	
CP	YEAGER et al., "An unpoled synthon approach to the synthesis of 2-aryloxyphenols," Synthesis 1995, 28-30.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--